OS after disease progression to CART19. (A-D) OS after disease progression to CART19 estimated by Kaplan-Meier and compared by long-rank test; 95% CI. (A) Patients treated on or off clinical trials; here, OS is defined for salvage therapy for disease progression post-CART19. (B) Patients who did not receive salvage therapy. (C) Patients eligible vs ineligible for landmark trials. (D) Patients eligible vs ineligible for anti-CD20 bispecific antibodies trials.